[go: up one dir, main page]

MA35184B1 - Antagonistes de trpv4 - Google Patents

Antagonistes de trpv4

Info

Publication number
MA35184B1
MA35184B1 MA36564A MA36564A MA35184B1 MA 35184 B1 MA35184 B1 MA 35184B1 MA 36564 A MA36564 A MA 36564A MA 36564 A MA36564 A MA 36564A MA 35184 B1 MA35184 B1 MA 35184B1
Authority
MA
Morocco
Prior art keywords
trpv4
compounds
antagonists
relates
spirocarbamate
Prior art date
Application number
MA36564A
Other languages
English (en)
Inventor
Carl Brooks
Mui Cheung
Hilary Schenck Eidam
Krista B Goodman
Marlys Hammond
Mark A Hilfiker
Tram H Hoang
Jaclyn R Patterson
Patrick Stoy
Guosen Ye
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35184(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA35184B1 publication Critical patent/MA35184B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de spirocarbamate de formule (i) dans laquelle r1, (r2)y, r3, r4, x et a étant tels que définis dans la description. Par ailleurs, l'invention concerne des compositions pharmaceutiques contenant ces composés ou des sels pharmaceutiquement acceptables de ceux-ci, ainsi que l'utilisation de ces composés comme antagonistes de trpv4 dans le traitement ou la prévention d'états pathologiques associés au déséquilibre de trpv4.
MA36564A 2011-06-17 2013-12-13 Antagonistes de trpv4 MA35184B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17
PCT/US2012/042622 WO2013012500A1 (fr) 2011-06-17 2012-06-15 Antagonistes de trpv4

Publications (1)

Publication Number Publication Date
MA35184B1 true MA35184B1 (fr) 2014-06-02

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36564A MA35184B1 (fr) 2011-06-17 2013-12-13 Antagonistes de trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (fr)
EP (2) EP2721016B1 (fr)
JP (1) JP5969017B2 (fr)
KR (1) KR101870003B1 (fr)
CN (1) CN103732583B (fr)
AR (1) AR086958A1 (fr)
AU (1) AU2012284540B2 (fr)
BR (1) BR112013032391B1 (fr)
CA (1) CA2839743C (fr)
CL (1) CL2013003602A1 (fr)
CO (1) CO6821953A2 (fr)
CR (1) CR20130671A (fr)
CY (1) CY1117792T1 (fr)
DK (1) DK2721016T3 (fr)
DO (1) DOP2013000307A (fr)
EA (1) EA023616B1 (fr)
ES (2) ES2688733T3 (fr)
HR (1) HRP20160539T1 (fr)
HU (1) HUE029594T2 (fr)
IL (1) IL229872A (fr)
JO (1) JO3154B1 (fr)
MA (1) MA35184B1 (fr)
ME (1) ME02416B (fr)
MX (1) MX337440B (fr)
MY (1) MY173521A (fr)
PE (1) PE20141943A1 (fr)
PH (1) PH12013502463A1 (fr)
PL (1) PL2721016T3 (fr)
PT (1) PT2721016E (fr)
RS (1) RS54858B1 (fr)
SG (1) SG195106A1 (fr)
SI (1) SI2721016T1 (fr)
SM (1) SMT201600150B (fr)
TW (1) TWI538912B (fr)
UA (1) UA113963C2 (fr)
UY (1) UY34138A (fr)
WO (1) WO2013012500A1 (fr)
ZA (1) ZA201308816B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5969016B2 (ja) 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
JP5969015B2 (ja) * 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
EP2832731A4 (fr) 2012-03-27 2015-08-19 Shionogi & Co Dérivé à noyau à cinq chaînons hétérocyclique aromatique ayant une activité inhibitrice de trpv4
WO2015046193A1 (fr) 2013-09-25 2015-04-02 塩野義製薬株式会社 Dérivé amine hétérocyclique aromatique présentant une activité inhibitrice de trpv4
AU2017266562A1 (en) * 2016-05-19 2018-11-15 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
EP3519413A1 (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica NV Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
WO2018185701A1 (fr) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Antagonistes de trpv4 en tant qu'agents antitussifs
CA3081424A1 (fr) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Composes spirocycliques a utiliser en tant que modulateurs du recepteur farnesoide x
WO2021170811A1 (fr) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Méthode de traitement d'une maladie oculaire à l'aide d'antagonistes de trpv4
MX2022013607A (es) 2020-04-30 2022-11-16 Raqualia Pharma Inc Derivados de la pirimidina-4(3h)-ona como antagonistas de trpv4.
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
KR20230041680A (ko) * 2020-07-16 2023-03-24 라퀄리아 파마 인코포레이티드 안구 질환 치료제로서의 trpv4 억제제
IL318209A (en) 2022-07-08 2025-03-01 Actio Biosciences Inc Medical compounds and methods
WO2024217429A1 (fr) * 2023-04-18 2024-10-24 河北乌图药业有限公司 Composé et son utilisation dans le traitement de l'hépatite b chronique, de la fibrose hépatique et du cancer du foie
CN120641413A (zh) * 2023-04-18 2025-09-12 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN121175303A (zh) * 2023-04-18 2025-12-19 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120225516A (zh) * 2023-04-18 2025-06-27 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN119855818A (zh) * 2023-04-18 2025-04-18 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2025014818A1 (fr) * 2023-07-07 2025-01-16 Actio Biosciences, Inc. Formes solides de gsk2798745, antagoniste de trpv4

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673797B1 (en) * 1998-05-26 2004-01-06 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
EP1644358A2 (fr) * 2003-07-16 2006-04-12 Neurogen Corporation Analogues de biaryl piperazinyl-pyridine
CN101346375B (zh) * 2005-11-23 2013-04-10 阿罗斯药物有限责任公司 调节门离子通道用组合物和方法
WO2007067756A2 (fr) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certains types d'entites chimiques, compositions et methode de modulation de trpv1
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
PE20081735A1 (es) * 2007-02-01 2009-01-18 Glaxo Group Ltd Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
WO2009023539A2 (fr) * 2007-08-09 2009-02-19 Abbott Laboratories Dérivés amides utilisés comme antagonistes des trpv1
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2010011914A1 (fr) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Antagoniste de trpv4
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
EP2605658B1 (fr) * 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Composés spiroxazolidinone
JP5969016B2 (ja) * 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
JP5969015B2 (ja) * 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬

Also Published As

Publication number Publication date
SI2721016T1 (sl) 2016-06-30
IL229872A (en) 2017-03-30
PL2721016T3 (pl) 2017-01-31
CL2013003602A1 (es) 2014-07-04
KR20140041733A (ko) 2014-04-04
PH12013502463A1 (en) 2014-01-20
SG195106A1 (en) 2013-12-30
HUE029594T2 (en) 2017-03-28
WO2013012500A1 (fr) 2013-01-24
US9187464B2 (en) 2015-11-17
ES2688733T3 (es) 2018-11-06
ES2569193T3 (es) 2016-05-09
MX2013014898A (es) 2014-03-21
EA201490037A1 (ru) 2015-12-30
EP2721016A4 (fr) 2014-10-08
SMT201600150B (it) 2016-07-01
TWI538912B (zh) 2016-06-21
UA113963C2 (xx) 2017-04-10
CO6821953A2 (es) 2013-12-31
MY173521A (en) 2020-01-30
DOP2013000307A (es) 2014-06-01
JP2014518214A (ja) 2014-07-28
CY1117792T1 (el) 2017-05-17
ZA201308816B (en) 2015-02-25
EP2721016A1 (fr) 2014-04-23
AR086958A1 (es) 2014-02-05
TW201313705A (zh) 2013-04-01
PT2721016E (pt) 2016-06-06
EP2721016B1 (fr) 2016-04-06
NZ618221A (en) 2015-02-27
BR112013032391B1 (pt) 2020-11-24
UY34138A (es) 2013-01-03
US20140121206A1 (en) 2014-05-01
CA2839743A1 (fr) 2013-01-24
AU2012284540A1 (en) 2013-04-04
AU2012284540B2 (en) 2014-08-28
EP3121177A1 (fr) 2017-01-25
MX337440B (es) 2016-03-03
CN103732583B (zh) 2015-12-23
ME02416B (fr) 2016-09-20
RS54858B1 (sr) 2016-10-31
BR112013032391A2 (pt) 2016-08-16
EP3121177B1 (fr) 2018-08-01
HRP20160539T1 (hr) 2016-06-17
EA023616B1 (ru) 2016-06-30
HK1195068A1 (zh) 2014-10-31
CN103732583A (zh) 2014-04-16
KR101870003B1 (ko) 2018-06-22
CA2839743C (fr) 2017-03-28
JO3154B1 (ar) 2017-09-20
DK2721016T3 (en) 2016-06-06
CR20130671A (es) 2014-02-04
PE20141943A1 (es) 2014-12-28
JP5969017B2 (ja) 2016-08-10

Similar Documents

Publication Publication Date Title
MA35184B1 (fr) Antagonistes de trpv4
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA37929A1 (fr) Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch
MA35576B1 (fr) Nouveaux composés
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire